Characterizing novel lung carcinoma cultures for drug target discovery and validation

This project develops and applies an economical, compact in vitro model to study the chronic effects of e-cigarette vapors on primary human airway mucociliary tissue cultures. Motivated by the public health challenge posed by widespread e-cigarette use and the 2019 emergence of e-cigarette or vaping use-associated lung injury (EVALI), the team designed and built a simple device capable of operating e-cigarettes and delivering their vapor directly into chambers holding standard multi-well cell culture plates. This platform enables controlled, repeatable exposures of primary human airway mucociliary tissue to aerosols generated from common vape-liquid formulations. Using this system, the investigators compared the effects of vapors produced from two relevant diluents: the widely used propylene glycol:vegetable glycerin mixture (PG:VG) that commonly carries nicotine, and vitamin E acetate (VEA), a diluent implicated in EVALI cases associated with illicit vape products.

The work demonstrates that PG:VG and VEA vapors interact with and alter airway tissue cultures in distinct ways, and the authors propose potential mechanisms by which VEA-containing vapors could exacerbate or precipitate EVALI symptoms. By employing primary human airway mucociliary cultures rather than immortalized cell lines or animal tissues, the model more closely represents human respiratory epithelium, including the mucociliary apparatus that is central to airway defense. The device and culture system together provide an animal-free experimental framework to investigate both acute and chronic consequences of vapor exposures on primary respiratory cells, facilitating mechanistic studies of cellular responses, barrier integrity, mucociliary function, and tissue-level pathology.

The study emphasizes the affordability and compactness of the platform, suggesting broad accessibility for laboratories seeking to perform translational respiratory toxicology without the complexity or cost associated with whole-animal models or large-scale inhalation chambers. Published in Toxicology in Vitro (2024, Volume 94, Article 105725; DOI: 10.1016/j.tiv.2023.105725), the work contributes a reproducible methodological advance and initial comparative findings that inform understanding of how different vape-liquid constituents might differentially affect airway tissue health. Beyond the immediate findings regarding PG:VG versus VEA vapors, the platform positions researchers to extend investigations into ingredient-specific toxicities, dose–response relationships, chronic exposure paradigms, and interactions with host factors. The model can support drug target identification and validation efforts by enabling screening of molecular pathways perturbed by vapor exposure and testing of candidate interventions in a human-relevant tissue context.

Given the ongoing prevalence of e-cigarette use and the potential for emergent lung injuries tied to specific diluents, this in vitro approach provides a practical, ethically favorable tool to advance respiratory toxicology, inform regulatory considerations, and guide safer product formulation and clinical management strategies.